NCT06457334 Effect of Helicobacter Pylori Eradication on Gastroesophageal RefIux Disease (GERD)
| NCT ID | NCT06457334 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assiut University |
| Condition | GERD |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-01-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluate the effect of H.pylori eradication on Gastroesophageal-reflux disease and symptoms improvement
Eligibility Criteria
Inclusion Criteria: * All patients diagnosed as GERD clinically and endscopically. Exclusion Criteria: * NO exclusion criteria
Contact & Investigator
Saad Z Mahmoud, Professor
STUDY DIRECTOR
Assiut University
Frequently Asked Questions
Who can join the NCT06457334 clinical trial?
This trial is open to participants of all sexes, studying GERD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06457334 currently recruiting?
Yes, NCT06457334 is actively recruiting participants. Contact the research team at sarafergany139@gmail.com for enrollment information.
Where is the NCT06457334 trial being conducted?
This trial is being conducted at Asyut, Egypt.
Who is sponsoring the NCT06457334 clinical trial?
NCT06457334 is sponsored by Assiut University. The principal investigator is Saad Z Mahmoud, Professor at Assiut University. The trial plans to enroll 100 participants.